Related Experiment Video
Updated: Jan 10, 2026
Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation
Published on: August 13, 2013
TCF21 Downregulation Induces ERO1A Expression and Upregulates IDO1 to Trigger Immune Escape in Lung Adenocarcinoma
1Respiratory Medicine, Jiashan County First People's Hospital, Jiaxing, China.
Abstract:
Transcription factor TCF21 is downregulated in lung adenocarcinoma (LUAD), contributing to poor treatment outcomes. This study explores its role in regulating CD8+ T cell-mediated antitumor immunity and metastasis. TCF21 expression was analyzed via TCGA. Downstream target ERO1A was identified using JASPAR prediction, validated by dual-luciferase/ChIP assays. LUAD mouse models and cell experiments (Transwell, flow cytometry, LDH/ELISA) assessed impacts on metastasis and CD8+ T cell function. The results showed that TCF21 overexpression inhibited LUAD migration/invasion and enhanced CD8+ T cell cytotoxicity. Mechanistically, TCF21 repressed ERO1A transcription, reducing IDO1 expression. Conversely, ERO1A overexpression promoted metastasis and suppressed CD8+ T cell activity via IDO1 upregulation. Knockdown of ERO1A or IDO1 blockade reversed the pro-tumor effects of TCF21 loss. In conclusion, TCF21 downregulation in LUAD activates the ERO1A-IDO1 axis, enabling immune escape from CD8+ T cell killing and accelerating malignancy.
Insights
Transcription factor TCF21 loss in lung adenocarcinoma (LUAD) promotes metastasis and immune evasion. Restoring TCF21 function may enhance CD8+ T cell therapy effectiveness against cancer.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Transcription factor TCF21 is downregulated in lung adenocarcinoma (LUAD), correlating with poor treatment outcomes.
- Understanding TCF21's role in antitumor immunity and metastasis is crucial for developing novel LUAD therapies.
Purpose of the Study:
- To investigate the function of TCF21 in regulating CD8+ T cell-mediated antitumor immunity and LUAD metastasis.
- To elucidate the molecular mechanisms underlying TCF21's effects on LUAD progression and immune surveillance.
Main Methods:
- TCGA data analysis for TCF21 expression.
- JASPAR prediction and dual-luciferase/ChIP assays to identify and validate TCF21 targets.
- LUAD mouse models and in vitro cell experiments (Transwell, flow cytometry, LDH/ELISA) to assess metastasis and CD8+ T cell function.
Main Results:
- TCF21 overexpression inhibited LUAD cell migration and invasion while enhancing CD8+ T cell cytotoxicity.
- TCF21 repressed ERO1A transcription, subsequently reducing IDO1 expression.
- ERO1A overexpression promoted LUAD metastasis and suppressed CD8+ T cell activity via IDO1 upregulation; ERO1A knockdown or IDO1 blockade reversed these effects.
Conclusions:
- TCF21 downregulation in LUAD activates the ERO1A-IDO1 axis, facilitating immune escape from CD8+ T cell-mediated killing.
- Targeting the ERO1A-IDO1 pathway could restore TCF21 function and enhance antitumor immunity in LUAD.
